EHA 2022 | Updates from a Phase I study evaluating dendritic cell therapy, cryosurgery & pembrolizumab in NHL
Yi Lin
• 11 Jun 2022
In this video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some updates from a Phase I study evaluating dendritic cell therapy, cryosurgery, and pembrolizumab for the treatment of non-Hodgkin lymphoma (NHL). Dr Lin first explains the biology behind dendritic cell therapy, and then goes on to discuss some of the results obtained. To conclude, Dr Lin highlights the potential role of this approach in deepening responses in the post-CAR-T setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
